Preliminary report on activity and tolerability of epomediol, administered by intravenous infusion, in patients with chronic hepatopathies.
The therapeutic activity and tolerability of epomediol were studied in 28 patients with chronic hepatopathies. Treatment was continued, parenterally, for 10 days (400-600 mg once daily by intravenous infusion). Clinical parameters (headache, right hypochondrial pain, bitter taste in the mouth, asthenia and nausea) and hepatic function (transaminase, alkaline phosphatase and gamma-glutamyl transpeptidase) showed significant improvements. Clinical and systemic tolerabilities of epomediol were satisfactory.
Mazzeo
F
F
Gastroenterology and Endoscopy Centre, Borgonovo Val Tidone Hospital, Piacenza, Italy.
Bernocchi
D
D
Cavalli
C
C
Manini
G
G
D000328:Adult; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003875:Drug Eruptions; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013729:Terpenes / Q000009:adverse effects / Q000627:therapeutic use*
D019086:Bridged Bicyclo Compounds, Heterocyclic; D013729:Terpenes; C031365:epomediol